… In this review, we provide an overview of nasal vaccines with a focus on formulation …
Here, we provide examples of intranasal vaccines that are being developed against SARS-CoV-2, …

… In this article, the current approaches used to develop effective oral and nasal mucosal
vaccines against SARS‐CoV‐2 and their benefits, prospects, and challenges have been …

… jeopardize vaccine efficacy. We recently reported the protective activity of an intranasally
administered spike protein-based chimpanzee adenovirus-vectored vaccine (ChAd-SARS-CoV-…

… So far, all the approved vaccines are by intramuscular (IM) injection only, although different
… on development of an intranasal (IN) SARS-CoV-2 vaccine. Ideally a vaccine, at least against …

… vaccine-platforms, which are safe, effective, and can be modified to carry antigens of emerging
pathogens. The current SARS-CoV-2 vaccines … a novel SARS-CoV-2 vaccine candidate …

… vaccine efficacy and inhibit lung deleterious injury in golden hamsters, which are naturally
permissive to SARS-CoV-… -based vaccination against SARS-CoV-2 and designate intranasal …

… 2 virus breaches before dissemination to the lung. We report the development of an intranasal
subunit vaccine … This vaccine induces systemic neutralizing antibodies, IgA in the lung and …

… intranasally administered ChAdOx1 nCoV-19 reduces detection of virus in nasal swabs
after challenging vaccinated macaques and hamsters with SARS-CoV-2 carrying a D614G …

… At 3 days after SARS-CoV-2 challenge, intranasally vaccinated hamsters had lower viral
loads in both the lung and nasal turbinates relative to mock vaccination, as determined by …

… The development of SARS-CoV-2 vaccines is diverse, and the development of nasal
vaccines is mainly focused on viral vector vaccines and protein subunit vaccines. As a …